查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
到 2028 年的肺动脉高压市场预测——COVID-19 的影响以及按药剂、类型、给药途径和分销渠道进行的全球分析
市场调查报告书
商品编码
1187270

到 2028 年的肺动脉高压市场预测——COVID-19 的影响以及按药剂、类型、给药途径和分销渠道进行的全球分析

Pulmonary Arterial Hypertension Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Drugs, Type, Route of Administration, and Distribution Channel
出版日期: | 出版商: The Insight Partners | 英文 174 Pages | 商品交期: 1-5个工作天内

价格

肺动脉高压市场预计将从 2021 年的 736989 万美元增长到 2028 年的 1088908 万美元，预计 2022 年至 2028 年的复合年增长率为 5.8%。 肺动脉高压发病率上升和治疗肺动脉高压药物的批准增加推动了市场增长。 然而，用于治疗肺动脉高压的药物的副作用阻碍了市场增长。

肺动脉高压 (PAH) 是一种罕见的进行性疾病，由肺动脉高压（高血压）引起。 由于多种原因，小肺动脉阻塞可能导致血管内压升高。 PAH 的确切病因尚不清楚，虽然它是可以治疗的，但它不是一种永久性疾病。 PAH 通常影响 30 至 60 岁的女性。

专利到期将使仿製药进入肺动脉高压市场，丰富产品线。 未来7-8年到2030年，专利到期的产品有望上市。 这将是未来几年仿製药公司的一个巨大机遇。 Gilead Sciences 的 Ambrisentan + Tadalafil用于治疗PAH，但其专利将于2027年12月11日到期。 Care Ratings 发现许多製药公司已经在开发其专利产品的仿製药。 专利到期后，仿製药就可以使用了。 虽然消费者受益于较低的价格，但专利保护的丧失使製药公司面临更激烈的竞争。 因此，预计专利到期将为仿製药製造商在预测期内进入新市场提供机会。

此外，在过去 20 年中出现了 14 种经 FDA 批准的治疗 PAH 的疗法，这是一项重大成就，因为该病的人群较少。这是有可能的。 成功开发 PAH 疗法的关键是在理解该疾病的遗传和分子机制方面取得重大进展。 随着这种意识的增强，治疗策略也将继续发展，并从目前专注于血管收缩的范例中多样化。 临床试验正在探索新输送装置的临床疗效及其在其他肺动脉高压和联合疗法中的应用。 这很可能成为未来临床试验的标准。

基于给药途径的见解

根据给药途径，肺动脉高压市场分为口服、静脉/皮下和吸入。 口腔部分将在 2021 年占据最大的肺动脉高压市场份额，预计在预测期内的复合年增长率最高。 用于治疗症状性中度至重度 PAH 的口服药物包括西地那非和内皮素 (ET) 受体拮抗剂 (ERA)、波生坦和西他生坦，与波生坦相比增加了 ET 受体亲和力。选择性时代。 此外，用于治疗 PAH 的新型口服药物包括 machitentan、riociguat 和 treprostinil。 Ambrisentan 是一种内皮素受体拮抗剂，适用于治疗 PAH（WHO 第 1 类），可以延缓临床恶化。 安立生坦与他达拉非联合使用可降低因疾病进展和 PAH 加重而住院的风险，并可改善运动成绩。

在预测期内，北美肺动脉高压市场所占份额最大。 该地区的市场增长归因于肺动脉高压的高患病率、政府和製造商的举措。 美国肺动脉高压市场在区域市场中占有很大份额。 儘管是一种罕见疾病，但 PAH 在美国的患病率要高得多。 据美国肺臟协会称，肺动脉高压是一种罕见的进行性疾病，美国每年约有 500 至 1,000 例新诊断病例。 据该协会称，由于基因突变，15-20%的肺动脉高压患者是遗传性肺动脉高压。

此外，製造商正在努力为医疗保健专业人员提供信息和资源，这推动了市场的增长。 由 United Therapeutics 支持的 PAH Initiative 提供资源和信息，以协助医疗保健专业人员治疗 PAH 患者。 此外，美国肺动脉高压科学登记处作为美国第一个 PAH 患者登记处成立，用于检查患者群体的遗传信息、生育史和环境暴露数据。 因此，每年诊断出的 PAH 病例数量不断增加，以及製造商的努力，正在推动对肺动脉高压药物和其他治疗方式的需求，导緻美国肺动脉高压的上升，进一步推动市场增长。

加拿大在北美肺动脉高压市场占有第二大份额。 加拿大的肺动脉高压患病率很高。 据 PHA Canada 估计，该国约有 10,000 人患有肺动脉高压 (PH)，但已诊断出约 5,000 人。 加拿大批准了有限数量的药物来减缓肺动脉高压的进展或缓解症状。 在过去 20 年中，加拿大仅批准了 10 种 PAH 治疗方法。 但是，全国各地都有专门治疗成人和儿童 PAH 的中心。 此外，发表在《欧洲呼吸杂誌》(2022) 上的一项研究报告称，加拿大 PAH 人群的 1 年、3 年和 5 年生存率分别为 89.2%、75.6% 和 56.0%。 因此，据报导，加拿大的 PAH 患者长期死亡率很高。

世界卫生组织 (WHO)、美国食品和药物管理局 (FDA)、美国罕见病组织 (NORD) 和其他组织在准备关于肺动脉高压市场的报告时参考了主要和次要信息。

内容

第一章介绍

  • 调查范围
  • Insight Partners 研究报告指南
  • 市场细分
    • 全球肺动脉高压市场 - 按药物分类
    • 全球肺动脉高压市场 - 按类型
    • 全球肺动脉高压市场 - 按给药途径
    • 全球肺动脉高压市场 - 按分销渠道
    • 全球肺动脉高压市场 - 按地区

第 2 章肺动脉高压市场——要点

第三章研究方法论

  • 范围
  • 二次调查
  • 初步调查

第 4 章肺动脉高压市场——市场格局

  • 害虫分析
    • 北美 PEST 分析
    • 欧洲 PEST 分析
    • 亚太地区 PEST 分析
    • 中东和非洲 PEST 分析
    • 拉丁美洲 PEST 分析
  • 专家意见

第 5 章肺动脉高压市场 - 主要市场动态

  • 市场驱动力
    • 肺动脉高压患病率增加
    • 肺动脉高压药物的批准增加
  • 市场製约因素
    • 用于治疗肺动脉高压的药物的副作用
  • 市场机会
    • 专利到期时间的增加使得仿製药可以以可承受的价格获得
    • 医药专利到期数据
  • 未来趋势
    • 肺动脉高压药物开发的临床试验增加
  • 影响分析

第 6 章肺动脉高压市场 - 全球分析

  • 肺动脉高压全球市场收入、预测和分析
  • 全球肺动脉高压市场：按地区划分的预测和分析
  • 主要参与者的市场定位

第 7 章：全球肺动脉高压市场 - 收入和到 2028 年的预测 - 按代理

  • 2021 年和 2028 年肺动脉高压市场收入份额（按药物）（%）
  • 内皮素受体拮抗剂 (ERA)
  • 前列环素和前列环素类似物
  • SGC 兴奋剂
  • Pde-5 试纸

第 8 章全球肺动脉高压市场分析和预测到 2028 年 - 按类型

  • 2021 年和 2028 年按类型划分的全球肺动脉高压市场 (%)
  • 品牌产品
  • 仿製药

第 9 章全球肺动脉高压市场 - 收入和到 2028 年的预测 - 按给药途径

  • 2021 年和 2028 年按给药途径划分的肺动脉高压市场收入份额 (%)
  • 口服剂
  • 静脉内/皮下
  • 吸入给药

第 10 章全球肺动脉高压市场 - 到 2028 年的收入和预测 - 按分销渠道

  • 2021 年和 2028 年肺动脉高压市场收入份额（按分销渠道）(%)
  • 医院药房/诊所
  • 在线药店
  • 零售药房

第 11 章肺动脉高压市场 - 收入和到 2028 年的预测 - 区域分析

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳大利亚
    • 其他亚太地区
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲
  • 中东和非洲
    • 阿联酋
    • 沙特阿拉伯
    • 南非
    • 其他中东和非洲地区

第 12 章 COVID-19 大流行对肺动脉高压市场的影响

  • 北美
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 中东和非洲

第 13 章肺动脉高压市场 - 行业格局

  • 肺动脉高压市场增长战略 (%)
  • 有机部署
  • 无机开发

第14章公司简介

  • Johnson & Johnson
  • Gilead Sciences Inc
  • United Therapeutics Corp
  • Bayer AG
  • Aerami Therapeutics Holdings Inc
  • Novartis AG
  • GSK Plc
  • Teva Pharmaceutical Industries Ltd
  • Lupin Ltd
  • Pfizer Inc

第15章附录

  • 关于 Insight Partners
  • 词彙表
Product Code: TIPRE00005221

The pulmonary arterial hypertension market is expected to grow from US$ 7,369.89 million in 2021 to US$ 10,889.08 million by 2028; it is estimated to grow at a CAGR of 5.8% from 2022 to 2028. The market growth is attributed to the growing incidence of pulmonary arterial hypertension and the rising approvals of pulmonary arterial hypertension drugs. However, the side effects of drugs used to treat pulmonary arterial hypertension hamper the market growth.

Pulmonary arterial hypertension (PAH) is a rare, progressive disorder caused due to high blood pressure (hypertension) in the arteries of the lungs. The increased pressure in the vessels may be caused by an obstruction in the small arteries in the lung for various reasons. The exact cause of PAH is unknown and although treatable; there is no permanent cure for the disease. PAH usually affects women between the age of 30-60 years..

Patent expiry permits generic drugs to penetrate the pulmonary arterial hypertension market and diversify product offerings. Over the next seven-eight years till 2030, the patented products are expected to go off-patent. This would provide an enormous opportunity for generic formulation companies in the coming years. AMBRISENTAN + TADALAFIL drug by Gilead Sciences, Inc. is used to treat PAH, and its patent will be expired by December 11, 2027. Many pharma companies are already working to develop the generic version of patented products, finds Care Ratings. After patent expiration, generic versions of drugs can become available. While consumers benefit from low prices, losing patent protection can expose pharmaceutical companies to growing competition. Thus, patent expiration is expected to open an opportunity for generic drug manufacturers to enter a new market during the forecast period.

Moreover, over the past 20 years, the arrival of 14 FDA-approved therapies for treating PAH is seen as a major feat considering that this disease affects a small population. The key to success in developing PAH therapies has been the immense advances in understanding the genetic and molecular mechanisms that drive the pathogenesis of the disease. With the growing awareness, the treatment strategies will continue to evolve and diversify from the current paradigm focused on vasoconstriction. Clinical trials are exploring the clinical efficacy of novel delivery devices and their utility in other forms of pulmonary hypertension and combination therapies. This will be the standard for clinical trials in the future.

Route of Administration-Based Insights

Based on route of administration, the pulmonary arterial hypertension market is segmented into oral, intravenous/subcutaneous, and inhalational. The oral segment held the largest pulmonary arterial hypertension market share in 2021 and is anticipated to register the highest CAGR during the forecast period. Orally administered agents used for the treatment of symptomatic, moderate-to-severe PAH include sildenafil and the endothelin (ET) receptor antagonists (ERAs), bosentan and sitaxentan (sitaxsentan), and abrisentan oral ET(A) receptor-selective ERA, with higher ET receptor affinity than bosentan. Moreover, new oral drugs for treating PAH include macitentan, riociguat, and treprostinil. Ambrisentan is an endothelin receptor antagonist indicated for treating PAH; WHO Group 1 and delay clinical worsening. In combination with tadalafil, ambrisentan is indicated to reduce the risks of disease progression and hospitalization for worsening PAH, and to improve exercise ability..

The pulmonary arterial hypertension market in North America held the largest share in the forecast period. The market growth in the region is attributed to the high prevalence of pulmonary arterial hypertension and initiatives by the government and manufacturers. The US pulmonary arterial hypertension market holds a significant share of the regional market. The prevalence of PAH in the US is much higher, although it is a rare disease. According to the American Lung Association, PAH is a rare and progressive disorder that accounts for about 500-1,000 new cases being diagnosed each year in the US. Additionally, as per the same source, ~15-20% of PAH patients have heritable PAH caused by genetic mutations.

Further, manufacturers undergo various initiatives to provide information and resources to healthcare practitioners, fueling the market growth. The PAH Initiative supported by United Therapeutics provides resources and information to assist healthcare providers in treating patients affected by PAH. In addition, the United States Pulmonary Hypertension Scientific Registry was established as the first US PAH patient registry to investigate genetic information, reproductive histories, and environmental exposure data in a patient population. Thus, the rising cases of PAH diagnosed each year and initiatives undertaken by manufacturers fuel the demand for pulmonary arterial hypertension drugs and other treatment methods, further bolstering the pulmonary arterial hypertension market growth in the US.

Canada holds the second-largest share of the pulmonary arterial hypertension market in North America. Canada has a high prevalence of pulmonary arterial hypertension. According to the PHA Canada, it is estimated that ~10,000 population in the country are affected by pulmonary hypertension (PH), but ~5,000 have been diagnosed with it. A limited number of treatments are approved in Canada to slow the progression of PH and alleviate symptoms. Over the last two decades, only 10 PH-specific medical treatments have been approved in Canada for treating PAH. However, the centers specializing in treating PAH in adults and children are located across the country. Additionally, a study (2022) published in European Respiratory Journal reported that the 1-, 3- and 5-year survival rates in the Canadian PAH cohort were 89.2%, 75.6%, and 56.0%, respectively. Thus, PAH patients in Canada are reported to have a high death rate in the long term.

The World Health Organization (WHO), US Food and Drug Administration (FDA), and National Organization for Rare Disorders (NORD) are among the primary and secondary sources referred to while preparing the report on the pulmonary arterial hypertension market.

Reasons to Buy:

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the pulmonary arterial hypertension market.

Highlights key business priorities in order to assist companies to realign their business strategies.

The key findings and recommendations highlight crucial progressive industry trends in the global pulmonary arterial hypertension market, thereby allowing players across the value chain to develop effective long-term strategies.

Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.

Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.

Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 The Insight Partners Research Report Guidance
  • 1.3 Market Segmentation
    • 1.3.1 Global Pulmonary Arterial Hypertension Market - By Drugs
    • 1.3.2 Global Pulmonary Arterial Hypertension Market - By Type
    • 1.3.3 Global Pulmonary Arterial Hypertension Market - By Route of Administration
    • 1.3.4 Global Pulmonary Arterial Hypertension Market - By Distribution Channel
    • 1.3.5 Global Pulmonary Arterial Hypertension Market - By Geography

2. Pulmonary Arterial Hypertension Market - Key Takeaways

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. Pulmonary Arterial Hypertension Market - Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
    • 4.2.1 North America PEST Analysis
    • 4.2.2 Europe PEST Analysis
    • 4.2.3 Asia Pacific PEST Analysis
    • 4.2.4 Middle East and Africa PEST Analysis
    • 4.2.5 South and Central America PEST Analysis
  • 4.3 Experts Opinion

5. Pulmonary Arterial Hypertension Market - Key Market Dynamics

  • 5.1 Market Drivers
    • 5.1.1 Growing Incidence of Pulmonary Arterial Hypertension
    • 5.1.2 Rising Approvals of Pulmonary Arterial Hypertension Drugs
  • 5.2 Market Restraints
    • 5.2.1 Side Effects of Drugs Used for Treatment of Pulmonary Arterial Hypertension
  • 5.3 Market Opportunities
    • 5.3.1 Availability of Generics at Affordable Costs Due to Growing Patent Expiration
    • 5.3.2 Drugs Patents Expiration Data
  • 5.4 Future Trend
    • 5.4.1 Rising Clinical Trials for Drugs Development to Treat Pulmonary Arterial Hypertension
  • 5.5 Impact analysis

6. Pulmonary Arterial Hypertension Market - Global Analysis

  • 6.1 Global Pulmonary Arterial Hypertension Market Revenue Forecast and Analysis
  • 6.2 Global Pulmonary Arterial Hypertension Market, By Geography - Forecast and Analysis
  • 6.3 Market Positioning of Key Players

7. Global Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 - by Drugs

  • 7.1 Overview
  • 7.2 Pulmonary Arterial Hypertension Market Revenue Share, by Drugs 2021 & 2028 (%)
  • 7.3 Endothelin Receptor Antagonists (ERAs)
    • 7.3.1 Overview
    • 7.3.2 Endothelin Receptor Antagonists (ERAs): Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • 7.4 Prostacyclin and Prostacyclin Analogs
    • 7.4.1 Overview
    • 7.4.2 Prostacyclin and Prostacyclin Analogs: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • 7.5 SGC Stimulators
    • 7.5.1 Overview
    • 7.5.2 SGC Stimulators: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • 7.6 Pde-5 Dipsticks
    • 7.6.1 Overview
    • 7.6.2 Pde-5 Dipsticks: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)

8. Global Pulmonary Arterial Hypertension Market Analysis and Forecasts to 2028 - by Type

  • 8.1 Overview
  • 8.2 Global Pulmonary Arterial Hypertension Market, by Type 2021 & 2028 (%)
  • 8.3 Branded
    • 8.3.1 Overview
    • 8.3.2 Branded: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • 8.4 Generics
    • 8.4.1 Overview
    • 8.4.2 Generics: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)

9. Global Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 - by Route of Administration

  • 9.1 Overview
  • 9.2 Pulmonary Arterial Hypertension Market Revenue Share, by Route of Administration 2021 & 2028 (%)
  • 9.3 Oral
    • 9.3.1 Overview
    • 9.3.2 Oral: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • 9.4 Intravenous/ Subcutaneous
    • 9.4.1 Overview
    • 9.4.2 Intravenous/ Subcutaneous: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • 9.5 Inhalational
    • 9.5.1 Overview
    • 9.5.2 Inhalational: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)

10. Global Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 - by Distribution Channel

  • 10.1 Overview
  • 10.2 Pulmonary Arterial Hypertension Market Revenue Share, by Distribution Channel 2021 & 2028 (%)
  • 10.3 Hospital Pharmacies and Clinics
    • 10.3.1 Overview
    • 10.3.2 Hospital Pharmacies and Clinics: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • 10.4 Online Pharmacies
    • 10.4.1 Overview
    • 10.4.2 Online Pharmacies: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • 10.5 Retail Pharmacies
    • 10.5.1 Overview
    • 10.5.2 Retail Pharmacies: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)

11. Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 - Geographic Analysis

  • 11.1 North America: Pulmonary Arterial Hypertension Market
    • 11.1.1 Overview
    • 11.1.2 North America: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
    • 11.1.3 North America: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
    • 11.1.4 North America: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
    • 11.1.5 North America: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
    • 11.1.6 North America: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
      • 11.1.6.1 US: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
        • 11.1.6.1.1 Overview
        • 11.1.6.1.2 US: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
        • 11.1.6.1.3 US: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
        • 11.1.6.1.4 US: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
        • 11.1.6.1.5 US: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
        • 11.1.6.1.6 US: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
      • 11.1.6.2 Canada: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
        • 11.1.6.2.1 Overview
        • 11.1.6.2.2 Canada: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
        • 11.1.6.2.3 Canada: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
        • 11.1.6.2.4 Canada: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
        • 11.1.6.2.5 Canada: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
        • 11.1.6.2.6 Canada: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
      • 11.1.6.3 Mexico: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
        • 11.1.6.3.1 Overview
        • 11.1.6.3.2 Mexico: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
        • 11.1.6.3.3 Mexico: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
        • 11.1.6.3.4 Mexico: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
        • 11.1.6.3.5 Mexico: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
        • 11.1.6.3.6 Mexico: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
  • 11.2 Europe: Pulmonary Arterial Hypertension Market
    • 11.2.1 Overview
    • 11.2.2 Europe: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
    • 11.2.3 Europe: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
    • 11.2.4 Europe: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
    • 11.2.5 Europe: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
    • 11.2.6 Europe: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
    • 11.2.7 Europe: Pulmonary Arterial Hypertension Market, by Country, 2021 & 2028 (%)
      • 11.2.7.1 UK: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
        • 11.2.7.1.1 Overview
        • 11.2.7.1.2 UK: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
        • 11.2.7.1.3 UK: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
        • 11.2.7.1.4 UK: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
        • 11.2.7.1.5 UK: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
        • 11.2.7.1.6 UK: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
      • 11.2.7.2 Germany: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
        • 11.2.7.2.1 Overview
        • 11.2.7.2.2 Germany: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
        • 11.2.7.2.3 Germany: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
        • 11.2.7.2.4 Germany: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
        • 11.2.7.2.5 Germany: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
        • 11.2.7.2.6 Germany: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
      • 11.2.7.3 France: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
        • 11.2.7.3.1 Overview
        • 11.2.7.3.2 France: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
        • 11.2.7.3.3 France: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
        • 11.2.7.3.4 France: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
        • 11.2.7.3.5 France: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
        • 11.2.7.3.6 France: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
      • 11.2.7.4 Italy: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
        • 11.2.7.4.1 Overview
        • 11.2.7.4.2 Italy: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
        • 11.2.7.4.3 Italy: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
        • 11.2.7.4.4 Italy: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
        • 11.2.7.4.5 Italy: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
        • 11.2.7.4.6 Italy: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
      • 11.2.7.5 Spain: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
        • 11.2.7.5.1 Overview
        • 11.2.7.5.2 Spain: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
        • 11.2.7.5.3 Spain: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
        • 11.2.7.5.4 Spain: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
        • 11.2.7.5.5 Spain: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
        • 11.2.7.5.6 Spain: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
      • 11.2.7.6 Rest of Europe: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
        • 11.2.7.6.1 Overview
        • 11.2.7.6.2 Rest of Europe: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
        • 11.2.7.6.3 Rest of Europe: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
        • 11.2.7.6.4 Rest of Europe: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
        • 11.2.7.6.5 Rest of Europe: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
        • 11.2.7.6.6 Rest of Europe: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
  • 11.3 Asia Pacific: Pulmonary Arterial Hypertension Market
    • 11.3.1 Overview
    • 11.3.2 Asia Pacific: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
    • 11.3.3 Asia Pacific: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
    • 11.3.4 Asia Pacific: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
    • 11.3.5 Asia Pacific: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
    • 11.3.6 Asia Pacific: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
    • 11.3.7 Asia Pacific: Pulmonary Arterial Hypertension Market, by Country, 2021 & 2028 (%)
      • 11.3.7.1 China: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
        • 11.3.7.1.1 Overview
        • 11.3.7.1.2 China: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
        • 11.3.7.1.3 China: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
        • 11.3.7.1.4 China: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
        • 11.3.7.1.5 China Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
        • 11.3.7.1.6 China Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
      • 11.3.7.2 Japan: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
        • 11.3.7.2.1 Overview
        • 11.3.7.2.2 Japan: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
        • 11.3.7.2.3 Japan: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
        • 11.3.7.2.4 Japan: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
        • 11.3.7.2.5 Japan: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
        • 11.3.7.2.6 Japan: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
      • 11.3.7.3 India: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
        • 11.3.7.3.1 Overview
        • 11.3.7.3.2 India: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
        • 11.3.7.3.3 India: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
        • 11.3.7.3.4 India: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
        • 11.3.7.3.5 India: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
        • 11.3.7.3.6 India: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
      • 11.3.7.4 South Korea: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
        • 11.3.7.4.1 Overview
        • 11.3.7.4.2 South Korea: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
        • 11.3.7.4.3 South Korea: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
        • 11.3.7.4.4 South Korea: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
        • 11.3.7.4.5 South Korea: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
        • 11.3.7.4.6 South Korea: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
      • 11.3.7.5 Australia: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
        • 11.3.7.5.1 Overview
        • 11.3.7.5.2 Australia: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
        • 11.3.7.5.3 Australia: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
        • 11.3.7.5.4 Australia: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
        • 11.3.7.5.5 Australia: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
        • 11.3.7.5.6 Australia: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
      • 11.3.7.6 Rest of Asia Pacific: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
        • 11.3.7.6.1 Overview
        • 11.3.7.6.2 Rest of Asia Pacific: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
        • 11.3.7.6.3 Rest of Asia Pacific: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
        • 11.3.7.6.4 Rest of Asia Pacific: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
        • 11.3.7.6.5 Rest of Asia Pacific: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
        • 11.3.7.6.6 Rest of Asia Pacific: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
  • 11.4 South and Central America Pulmonary Arterial Hypertension Market
    • 11.4.1 Overview
    • 11.4.2 South and Central America: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
    • 11.4.3 South and Central America: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
    • 11.4.4 South and Central America: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
    • 11.4.5 South and Central America: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
    • 11.4.6 South and Central America: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
    • 11.4.7 South and Central America: Pulmonary Arterial Hypertension Market, by Country, 2021 & 2028 (%)
      • 11.4.7.1 Brazil: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
        • 11.4.7.1.1 Overview
        • 11.4.7.1.2 Brazil: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
        • 11.4.7.1.3 Brazil: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
        • 11.4.7.1.4 Brazil: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
        • 11.4.7.1.5 Brazil: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
        • 11.4.7.1.6 Brazil: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
      • 11.4.7.2 Argentina: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
        • 11.4.7.2.1 Overview
        • 11.4.7.2.2 Argentina: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
        • 11.4.7.2.3 Argentina: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
        • 11.4.7.2.4 Argentina: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
        • 11.4.7.2.5 Argentina: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
        • 11.4.7.2.6 Argentina: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
      • 11.4.7.3 Rest of South and Central America: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
        • 11.4.7.3.1 Overview
        • 11.4.7.3.2 Rest of South and Central America: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
        • 11.4.7.3.3 Rest of South and Central America: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
        • 11.4.7.3.4 Rest of South and Central America: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
        • 11.4.7.3.5 Rest of South and Central America: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
        • 11.4.7.3.6 Rest of South and Central America: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
  • 11.5 Middle East & Africa Pulmonary Arterial Hypertension Market
    • 11.5.1 Overview
    • 11.5.2 Middle East & Africa: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
    • 11.5.3 Middle East & Africa: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
    • 11.5.4 Middle East & Africa: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
    • 11.5.5 Middle East & Africa: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
    • 11.5.6 Middle East & Africa: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
    • 11.5.7 Middle East & Africa: Pulmonary Arterial Hypertension Market, by Country, 2021 & 2028 (%)
      • 11.5.7.1 UAE: Pulmonary Arterial Hypertension Market Revenue and Forecasts to 2028 (US$ Million)
        • 11.5.7.1.1 Overview
        • 11.5.7.1.2 UAE: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
        • 11.5.7.1.3 UAE: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
        • 11.5.7.1.4 UAE: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
        • 11.5.7.1.5 UAE: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
        • 11.5.7.1.6 UAE: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
      • 11.5.7.2 Saudi Arabia: Pulmonary Arterial Hypertension Market Revenue and Forecasts to 2028 (US$ Million)
        • 11.5.7.2.1 Overview
        • 11.5.7.2.2 Saudi Arabia: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
        • 11.5.7.2.3 Saudi Arabia: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
        • 11.5.7.2.4 Saudi Arabia: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
        • 11.5.7.2.5 Saudi Arabia: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
        • 11.5.7.2.6 Saudi Arabia: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
      • 11.5.7.3 South Africa: Pulmonary Arterial Hypertension Market Revenue and Forecasts to 2028 (US$ Million)
        • 11.5.7.3.1 Overview
        • 11.5.7.3.2 South Africa: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
        • 11.5.7.3.3 South Africa: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
        • 11.5.7.3.4 South Africa: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
        • 11.5.7.3.5 South Africa: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
        • 11.5.7.3.6 South Africa: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
      • 11.5.7.4 Rest of the Middle East and Africa: Pulmonary Arterial Hypertension Market Revenue and Forecasts to 2028 (US$ Million)
        • 11.5.7.4.1 Overview
        • 11.5.7.4.2 Rest of the Middle East and Africa: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
        • 11.5.7.4.3 Rest of the Middle East and Africa: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
        • 11.5.7.4.4 Rest of the Middle East and Africa: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
        • 11.5.7.4.5 Rest of the Middle East and Africa: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
        • 11.5.7.4.6 Rest of the Middle East and Africa: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)

12. Impact Of COVID-19 Pandemic on Pulmonary Arterial Hypertension Market

  • 12.1 North America: Impact Assessment of COVID-19 Pandemic
  • 12.2 Europe: Impact Assessment of COVID-19 Pandemic
  • 12.3 Asia Pacific: Impact Assessment of COVID-19 Pandemic
  • 12.4 South & Central America: Impact Assessment of COVID-19 Pandemic
  • 12.5 Middle East & Africa: Impact Assessment of COVID-19 Pandemic

13. Pulmonary Arterial Hypertension Market - Industry Landscape

  • 13.1 Overview
  • 13.2 Growth Strategies in the Pulmonary Arterial Hypertension Market (%)
  • 13.3 Organic Developments
    • 13.3.1 Overview
  • 13.4 Inorganic Developments
    • 13.4.1 Overview

14. Company Profiles

  • 14.1 Johnson & Johnson
    • 14.1.1 Key Facts
    • 14.1.2 Business Description
    • 14.1.3 Products and Services
    • 14.1.4 Financial Overview
    • 14.1.5 SWOT Analysis
    • 14.1.6 Key Developments
  • 14.2 Gilead Sciences Inc
    • 14.2.1 Key Facts
    • 14.2.2 Business Description
    • 14.2.3 Products and Services
    • 14.2.4 Financial Overview
    • 14.2.5 SWOT Analysis
    • 14.2.6 Key Developments
  • 14.3 United Therapeutics Corp
    • 14.3.1 Key Facts
    • 14.3.2 Business Description
    • 14.3.3 Products and Services
    • 14.3.4 Financial Overview
    • 14.3.5 SWOT Analysis
    • 14.3.6 Key Developments
  • 14.4 Bayer AG
    • 14.4.1 Key Facts
    • 14.4.2 Business Description
    • 14.4.3 Products and Services
    • 14.4.4 Financial Overview
    • 14.4.5 SWOT Analysis
    • 14.4.6 Key Developments
  • 14.5 Aerami Therapeutics Holdings Inc
    • 14.5.1 Key Facts
    • 14.5.2 Business Description
    • 14.5.3 Products and Services
    • 14.5.4 Financial Overview
    • 14.5.5 SWOT Analysis
    • 14.5.6 Key Developments
  • 14.6 Novartis AG
    • 14.6.1 Key Facts
    • 14.6.2 Business Description
    • 14.6.3 Products and Services
    • 14.6.4 Financial Overview
    • 14.6.5 SWOT Analysis
    • 14.6.6 Key Developments
  • 14.7 GSK Plc
    • 14.7.1 Key Facts
    • 14.7.2 Business Description
    • 14.7.3 Products and Services
    • 14.7.4 Financial Overview
    • 14.7.5 SWOT Analysis
    • 14.7.6 Key Developments
  • 14.8 Teva Pharmaceutical Industries Ltd
    • 14.8.1 Key Facts
    • 14.8.2 Business Description
    • 14.8.3 Products and Services
    • 14.8.4 Financial Overview
    • 14.8.5 SWOT Analysis
    • 14.8.6 Key Developments
  • 14.9 Lupin Ltd
    • 14.9.1 Key Facts
    • 14.9.2 Business Description
    • 14.9.3 Products and Services
    • 14.9.4 Financial Overview
    • 14.9.5 SWOT Analysis
    • 14.9.6 Key Developments
  • 14.10 Pfizer Inc
    • 14.10.1 Key Facts
    • 14.10.2 Business Description
    • 14.10.3 Products and Services
    • 14.10.4 Financial Overview
    • 14.10.5 SWOT Analysis
    • 14.10.6 Key Developments

15. Appendix

  • 15.1 About The Insight Partners
  • 15.2 Glossary of Terms

List Of Tables

  • Table 1. Drugs Patents Expiration Data
  • Table 2. North America Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
  • Table 3. North America Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 4. North America Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
  • Table 5. North America Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
  • Table 6. US Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
  • Table 7. US Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 8. US Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
  • Table 9. US Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
  • Table 10. Canada Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
  • Table 11. Canada Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 12. Canada Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
  • Table 13. Canada Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
  • Table 14. Mexico Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
  • Table 15. Mexico Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 16. Mexico Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
  • Table 17. Mexico Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
  • Table 18. Europe Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
  • Table 19. Europe Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 20. Europe Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
  • Table 21. Europe Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
  • Table 22. UK Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
  • Table 23. UK Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 24. UK Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
  • Table 25. UK Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
  • Table 26. Germany Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
  • Table 27. Germany Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 28. Germany Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
  • Table 29. Germany Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
  • Table 30. France Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
  • Table 31. France Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 32. France Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
  • Table 33. France Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
  • Table 34. Italy Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
  • Table 35. Italy Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 36. Italy Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
  • Table 37. Italy Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
  • Table 38. Spain Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
  • Table 39. Spain Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 40. Spain Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
  • Table 41. Spain Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
  • Table 42. Rest of Europe Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
  • Table 43. Rest of Europe Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 44. Rest of Europe Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
  • Table 45. Rest of Europe Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
  • Table 46. Asia Pacific Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
  • Table 47. Asia Pacific Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 48. Asia Pacific Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
  • Table 49. Asia Pacific Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
  • Table 50. China Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
  • Table 51. China Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 52. China Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
  • Table 53. China Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
  • Table 54. Japan Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
  • Table 55. Japan Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 56. Japan Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
  • Table 57. Japan Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
  • Table 58. India Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
  • Table 59. India Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 60. India Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
  • Table 61. India Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
  • Table 62. South Korea Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
  • Table 63. South Korea Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 64. South Korea Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
  • Table 65. South Korea Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
  • Table 66. Australia Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
  • Table 67. Australia Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 68. Australia Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
  • Table 69. Australia Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
  • Table 70. Rest of Asia Pacific Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
  • Table 71. Rest of Asia Pacific Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 72. Rest of Asia Pacific Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
  • Table 73. Rest of Asia Pacific Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
  • Table 74. South and Central America: Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
  • Table 75. South and Central America: Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 76. South and Central America: Pulmonary Arterial Hypertension Market, by Route of Administration- Revenue and Forecast to 2028 (US$ Million)
  • Table 77. South and Central America: Pulmonary Arterial Hypertension Market, by Distribution Channel- Revenue and Forecast to 2028 (US$ Million)
  • Table 78. Brazil: Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
  • Table 79. Brazil: Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 80. Brazil: Pulmonary Arterial Hypertension Market, by Route of Administration- Revenue and Forecast to 2028 (US$ Million)
  • Table 81. Brazil: Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
  • Table 82. Argentina: Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
  • Table 83. Argentina: Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 84. Argentina: Pulmonary Arterial Hypertension Market, by Route of Administration- Revenue and Forecast to 2028 (US$ Million)
  • Table 85. Argentina: Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
  • Table 86. Rest of South and Central America: Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
  • Table 87. Rest of South and Central America: Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 88. Rest of South and Central America: Pulmonary Arterial Hypertension Market, by Route of Administration- Revenue and Forecast to 2028 (US$ Million)
  • Table 89. Rest of South and Central America: Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
  • Table 90. Middle East & Africa Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
  • Table 91. Middle East & Africa Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 92. Middle East & Africa Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
  • Table 93. Middle East & Africa Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
  • Table 94. UAE Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
  • Table 95. UAE Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 96. UAE Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
  • Table 97. UAE Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
  • Table 98. Saudi Arabia Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
  • Table 99. Saudi Arabia Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 100. Saudi Arabia Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
  • Table 101. Saudi Arabia Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
  • Table 102. South Africa Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
  • Table 103. South Africa Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 104. South Africa Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
  • Table 105. South Africa Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
  • Table 106. Rest of the Middle East and Africa Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
  • Table 107. Rest of the Middle East and Africa Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 108. Rest of the Middle East and Africa Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
  • Table 109. Rest of the Middle East and Africa Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
  • Table 110. Organic Developments in the Pulmonary Arterial Hypertension Market
  • Table 111. Inorganic Developments in the Pulmonary Arterial Hypertension Market
  • Table 112. Glossary of Terms

List Of Figures

  • Figure 1. Pulmonary Arterial Hypertension Market Segmentation
  • Figure 2. Pulmonary Arterial Hypertension Market - By Geography
  • Figure 3. Pulmonary Arterial Hypertension Market Overview
  • Figure 4. Prostacyclin and Prostacyclin Analogs Segment Held Largest Share by Drugs of Pulmonary Arterial Hypertension Market
  • Figure 5. Asia Pacific to Show Significant Growth During Forecast Period
  • Figure 6. Pulmonary Arterial Hypertension Market, by Geography (US$ Million)
  • Figure 7. Global Pulmonary Arterial Hypertension Market - Leading Country Markets (US$ Million)
  • Figure 8. Global Pulmonary Arterial Hypertension Market, Industry Landscape
  • Figure 9. North America: PEST Analysis
  • Figure 10. Europe: PEST Analysis
  • Figure 11. Asia Pacific: PEST Analysis
  • Figure 12. Middle East and Africa: PEST Analysis
  • Figure 13. South and Central America: PEST Analysis
  • Figure 14. Experts Opinion
  • Figure 15. Pulmonary Arterial Hypertension Market Impact Analysis of Drivers and Restraint
  • Figure 16. Global Pulmonary Arterial Hypertension Market- Revenue Forecast and Analysis - 2020 - 2028
  • Figure 17. Global Pulmonary Arterial Hypertension Market - By Geography Forecast and Analysis - 2022 - 2028
  • Figure 18. Market Positioning of Key Players in Pulmonary Arterial Hypertension Market
  • Figure 19. Pulmonary Arterial Hypertension Market Revenue Share, by Drugs 2021 & 2028 (%)
  • Figure 20. Endothelin Receptor Antagonists (ERAs): Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 21. Prostacyclin and Prostacyclin Analogs: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 22. SGC Stimulators: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 23. Pde-5 Dipsticks: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 24. Global Pulmonary Arterial Hypertension Market, by Type 2021 & 2028 (%)
  • Figure 25. Branded: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 26. Generics: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 27. Pulmonary Arterial Hypertension Market Revenue Share, by Route of Administration 2021 & 2028 (%)
  • Figure 28. Oral: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 29. Intravenous/ Subcutaneous: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 30. Inhalational: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 31. Pulmonary Arterial Hypertension Market Revenue Share, by Distribution Channel 2021 & 2028 (%)
  • Figure 32. Hospital Pharmacies and Clinics: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 33. Online Pharmacies: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 34. Retail Pharmacies: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 35. North America: Pulmonary Arterial Hypertension Market, by Key Country - Revenue (2021) (US$ Million)
  • Figure 36. North America Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 37. North America: Pulmonary Arterial Hypertension Market, by Country, 2021 & 2028 (%)
  • Figure 38. US: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 39. Canada: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 40. Mexico: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 41. Europe: Pulmonary Arterial Hypertension Market, by Key Country - Revenue (2021) (US$ Million)
  • Figure 42. Europe Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 43. Europe: Pulmonary Arterial Hypertension Market, by Country, 2021 & 2028 (%)
  • Figure 44. Germany: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 45. Germany: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 46. France: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 47. Italy: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 48. Spain: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 49. Rest of Europe: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 50. Asia Pacific: Pulmonary Arterial Hypertension Market, by Key Country - Revenue (2021) (US$ Million)
  • Figure 51. Asia Pacific Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 52. China: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 53. Japan: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 54. India: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 55. South Korea: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 56. Australia: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 57. Rest of Asia Pacific: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 58. South and Central America: Pulmonary Arterial Hypertension Market, by Key Country - Revenue (2021) (US$ Million)
  • Figure 59. South and Central America Pulmonary Arterial Hypertension Market Revenue and Forecast to 2028 (US$ Million)
  • Figure 60. South and Central America: Pulmonary Arterial Hypertension Market, by Country, 2021 & 2028 (%)
  • Figure 61. Brazil: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 62. Argentina: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 63. Rest of South and Central America: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 64. Middle East & Africa: Pulmonary Arterial Hypertension Market, by Key Country - Revenue (2021) (US$ Million)
  • Figure 65. Middle East & Africa Pulmonary Arterial Hypertension Market Revenue and Forecast to 2028 (USD Million)
  • Figure 66. UAE: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 67. Saudi Arabia: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 68. South Africa: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 69. Rest of the Middle East and Africa: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 70. Impact of COVID-19 Pandemic in North America Country Markets
  • Figure 71. Impact of COVID-19 Pandemic in European Country Markets
  • Figure 72. Impact of COVID-19 Pandemic on Asia Pacific Country Markets
  • Figure 73. Impact of COVID-19 Pandemic in South and Central American Countries
  • Figure 74. Impact of COVID-19 Pandemic on Middle East and Africa Country Markets
  • Figure 75. Growth Strategies in the Pulmonary Arterial Hypertension Market (%)